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Digital health interventions have enormous potential as scalable tools to improve health and 
healthcare delivery by improving effectiveness, efficiency, accessibility, safety, and 
personalization. Achieving these improvements requires a cumulative knowledge base to 
inform development and deployment of digital health interventions. However, evaluations of 
digital health interventions present special challenges. This paper aims to examine these 
challenges and outline an evaluation strategy in terms of the research questions needed to 
appraise such interventions. As they are at the intersection of biomedical, behavioral, 
computing, and engineering research, methods drawn from all these disciplines are required. 
Relevant research questions include defining the problem and the likely benefit of the digital 
health intervention, which in turn requires establishing the likely reach and uptake of the 
intervention, the causal model describing how the intervention will achieve its intended 
benefit, key components, and how they interact with one another, and estimating overall 
benefit in terms of effectiveness, cost effectiveness, and harms. Although RCTs are important 
for evaluation of effectiveness and cost effectiveness, they are best undertaken only when: (1) 
the intervention and its delivery package are stable; (2) these can be implemented with high 
fidelity; and (3) there is a reasonable likelihood that the overall benefits will be clinically 
meaningful (improved outcomes or equivalent outcomes at lower cost). Broadening the 
portfolio of research questions and evaluation methods will help with developing the 
necessary knowledge base to inform decisions on policy, practice, and research. 
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Introduction 
There is enormous potential for digital health interventions (DHIs; i.e., interventions 
delivered via digital technologies such as smartphones, website, or text messaging) to provide 
effective, cost-effective, safe, and scalable interventions to improve health and healthcare. 
DHIs can be used to promote healthy behaviors (e.g., smoking cessation,1 healthy eating,2 
physical activity,3 safer sex,4 or alcohol consumption5); improve outcomes in people with 
long-term conditions6 such as cardiovascular disease,7 diabetes,8 and mental health 
conditions; 9and provide remote access to effective treatments (e.g., computerized cognitive 
behavioral therapy for mental health and somatic problems).10-13 They are typically complex 
interventions with multiple components, and many have multiple aims including enabling 
users to be better informed about their health, share experiences with others in similar 
positions, change perceptions and cognitions around health, assess and monitor specified 
health states or health behaviors, titrate medication, clarify health priorities and reach 
treatment decisions congruent with these, and improve communication between patients and 
healthcare professionals (HCPs). Active components may include information, psycho-
education, personal stories, formal decision aids, behavior change support, interactions with 
HCPs and other patients, self-assessment or monitoring tools (questionnaires, wearables, 
monitors), and effective theory-based psychological interventions developed for face-to-face 
delivery such as cognitive behavioral therapy or mindfulness training. 
 
To date, the potential of DHIs has scarcely been realized, partly because of difficulties in 
generating an accumulating knowledge base for guiding decisions about DHIs. These include 
the rapid change of the wider technology landscape 14, which requires DHIs to constantly 
evolve and be updated just to remain useful, let alone improve. For example, imagine an 
iPhone app promoting physical activity, with development and evaluation starting in 2008. 
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Results from an RCT may not be published for 5–6 years, by which time the iPhone 
operating system has undergone substantial changes to functionality, design, and overall use. 
These operating system changes would result in the evaluated app feeling out of date at best 
and non-functional at worst. As such, the knowledge gained from that efficacy trial would be 
minimally useful for supporting current decisions about using that app. Other difficulties 
include the idiosyncratic wants and needs of users and the influence of context on 
effectiveness. 
 
However, the public, patients, clinicians, policymakers, and healthcare commissioners have 
to make decisions on DHI now, and researchers need to support such decision making by 
creating an actionable knowledge base to identify the most effective, cost-effective, safe, and 
scalable interventions (and components) for improving individual and population health. 
These decisions are particularly important in resource-constrained contexts. 
 
This paper explores issues that arise in developing an accumulating knowledge base around 
DHIs, and how this knowledge can be generated in a timely manner, using scarce resources 
efficiently. The approach is pragmatic, with a focus on decision making and moving the 
science forward, generating cumulative knowledge around identifying important components, 
and working out how to test them with a view to improving the quality and effectiveness of 
DHIs and the efficiency of the research process. This paper is written from the perspective of 
a body charged with appraising evidence for using specific DHI within a publically funded, 
resource-limited health system, such as the United Kingdom National Institute for Health and 
Care Excellence. 
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This paper does not seek to provide detailed analysis of appropriate design features of 
evaluation studies such as choice of comparators, outcome measures, mediator and moderator 
variables, study samples, or the occasions when particular study designs are a better fit with 
the evaluation context. These are important issues for which a literature is beginning to 
emerge. 15, 16 
 
Paper Structure 
The paper starts by defining the research questions (RQs) that, in the authors’ opinion, should 
form the basis for an appraisal of a DHI (Table 1). It then considers appropriate research 
methods for each of these RQs. Where the appropriate methods are largely similar to those 
used in research of other (non-digital) complex interventions, readers are referred to the 
appropriate references. Where there are novel or specific issues that arise, or are particularly 
salient, in evaluation of DHIs, the main areas of consideration for each issue are outlined. 
Throughout, the paper emphasizes that the RQs apply not just to the digital components of 
the DHI, but also the surrounding “delivery package.” This package will vary according to 
the nature and functions of the DHI, but often requires as much thought and study as the DHI 
itself. Example components of delivery packages could include system redesign where use of 
DHIs becomes standard clinical practice,17 ad hoc referral from a clinician,18 supported 
access (e.g., face to face,19 by telephone,20 or by e-mail21), hosting on a trusted portal (e.g., 
National Health Service Choices), marketing via public health campaigns, or embedding in a 
social network. 
 
Research Questions: Defining the Problem 
Is There a Clear Health Need That This Digital Health Intervention Is Intended to Address?  And, 
is There a Defined Population Who Could Benefit From This Digital Health Intervention? 
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As with any complex intervention, consideration of the likely benefits of a DHI starts with a 
detailed and preferably theory-based characterization of the nature of the problem and the 
context in which the intervention will be used.22-24 
 
Research Questions: Defining the Likely Benefit of the Digital Health 
Intervention 
Is the Digital Health Intervention Likely to Reach This Defined Population, and  
If So, Is the Population Likely to Use it? 
The concepts of reach, uptake, and context are particularly salient for DHIs, as impact and 
cost effectiveness are highly dependent on the total number of users 25, and effectiveness may 
be highly dependent on context. For example, effects seen when a DHI is used in a controlled 
environment (laboratory or clinical office) may not be replicated if used in the “wild,” with 
many competing demands on users’ attention. An important consideration is whether a DHI 
is accessible across a range of commonly used operating systems and devices and is 
interoperable with other healthcare information systems, such as electronic health records. 
Hence, an early component of any evaluation of a DHI should be a determination and 
optimization of reach and uptake by the intended population, in the context in which the DHI 
will be used. This will often require iterative adaptations both to the DHI itself (e.g., to 
improve usability, acceptability) and to the “delivery package” around the DHI. For many 
DHIs, “users” will include HCPs who “prescribe” the DHI and monitor outcomes. Thus, RQs 
3–6 require work with HCPs as well as patients or the public. 
 
Establishing and optimizing potential reach and uptake require methods used in engineering 
and computer science, collectively referred to as human-centered design.26-28  These include 
concept sketching,29 co-design strategies,26 low-fidelity or “Wizard of Oz” prototyping,30, 31 
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and user experience testing.28 In the business world, there is increasing interest in “lean” 
principles that specify methods for early-stage testing of features related to feasibility 
including:32 
 
 acceptability and usability (Will the target audience (e.g., patients, HCPs) incorporate and 
sustain the intervention into their lives/clinical practice?); 
 demand (Will relevant stakeholders use it?); 
 implementation (Will it have high fidelity within real-world use?); 
 practicability (Can it be delivered with minimal burden?); 
 adaptation (Can it be adapted to novel contexts without compromising fidelity and 
integrity?); and 
 integration (Can it be integrated successfully into existing healthcare systems?). 
 
Is There a Credible Causal Explanation for the Digital Health Intervention to Achieve the Desired 
Impact? 
Establishing a credible causal explanation for the DHI is essential and must address not only 
the DHI, but also the “delivery package.” For example, if there is a human support element, is 
that element aimed entirely at improving engagement with the DHI, or will there be 
additional therapeutic content embedded in the human support? Are there important issues 
around the credibility or authority invested in those that deliver the human support?33, 34 
provide further discussion. 
 
What Are the Key Components of the Digital Health Intervention? Which Ones Impact On the 
Predicted Outcome, and How Do They Interact With Each Other? 
Understanding which components actually have the predicted impact on the outcome, and 
whether and how components interact, is critical. Most DHIs are highly complex 
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interventions, containing multiple components, so the development process needs to include a 
period of optimization. This entails evaluating the performance of individual components of 
the intervention, and how the presence, absence, or setting of one component impacts the 
performance of another. One efficient method is the Multiphase Optimization Strategy,35, 36 
which involves establishing a set of components that are candidates for inclusion, specifying 
an optimization criterion for the entire intervention, and then collecting experimental data to 
identify the subset of components that meet the criterion. Here, the term “component” is 
broadly defined, and may refer to aspects of the content of the intervention, including any 
human input;37 factors affecting compliance with, adherence to, fidelity of, or scalability of 
the intervention;38 variables and decision rules used to tailor intervention strategy, content, or 
intensity to individuals39; or any aspect of an intervention that can profitably be separated out 
for examination. Two example optimization criteria are the most effective intervention that 
can be delivered for <$100 per participant, or the most effective intervention that requires no 
more than 1 hour per week of participant time. 
 
The experimental approaches used for optimization include full or fractional factorial 
experiments,40, 41 the sequential multiple-assignment randomized trial (SMART)42 and system 
identification techniques.43, 44 The factorial experimental design can be a useful and 
economical approach for examining the effects of individual intervention components, and is 
the only experimental design that enables full examination of all interactions. This is 
discussed further in Collins et al. 40, 45 
 
1. What Strategies Should Be Used to Support Tailoring the Digital Health Intervention to 
Participants Over Time? 
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Where the RQ focuses on tailoring the DHI to participants over time (e.g., non-responders, or 
daily adjustments reflecting changing needs or context) a SMART design,46 micro-
randomized trial, or system identification experiment may be appropriate. A SMART is a 
special case of the factorial experiment involving randomization at several stages, where each 
stage corresponds to one of the decisions that must be made about adapting the intervention, 
and some or all of the randomization may be contingent on response to treatment. 35, 47 
 
System identification approaches are used in engineering to obtain dynamic systems models; 
these in turn are the basis for the design of control systems which achieve optimization.48 
System identification experiments are inherently idiographic in nature, and work best when 
planned changes (preferably random or pseudo-random in nature) are introduced to 
adjustable components of an intervention (e.g., dosages). After obtaining experimental data, 
the system identification methodology guides decisions of model structure, parameter 
estimation, and model validation prior to dictating the usefulness of the model for controller 
design. Examples can be found in Timms and colleagues49 and Deshpande et al 43; 
experimental procedures involving pseudo-random multisine signals are currently being 
evaluated in a physical activity intervention based on Social Cognitive Theory.50 
 
What is the Likely Direction and Magnitude of the Effect of the Digital Health Intervention or its 
Components Compared to a Comparator That is Meaningful for the Stage of the Research 
Process?  What is the Level of Confidence in this Effect? 
 
Once RQs 3–6 have been addressed, the research team is likely to be able to estimate the 
direction and magnitude of the effect of the DHI. If this estimate suggests that the DHI is 
likely to be beneficial to individuals or a population, has sufficient acceptability and 
feasibility to ensure adequate reach and uptake for cost effectiveness, and when the total 
10 
treatment package (i.e. DHI plus delivery package plus context of use) have all been iterated 
and adapted to the point where the treatment package is likely to remain relatively stable over 
the medium term, it may be appropriate to undertake a definitive RCT to establish the 
magnitude of the effect (effect size) of the DHI compared to a meaningful comparator. 
“Relatively stable” is a matter for investigator judgment, guided by the causal explanation 
and optimization data.51 The wider technologic landscape is likely to continue to evolve, and 
investigators must judge what impact this will have on the generalizability of their findings. 
The importance of undertaking an RCT and not relying solely on formative studies is 
evidenced by the fact that RCTs have repeatedly overturned assumptions drawn from 
observational or non-randomized studies (e.g 52, 53). Hence the assumption of equipoise, 
required for a trial to be ethical, does hold. Although the general principles of designing and 
conducting RCTs for complex interventions22 are applicable to DHIs, there are specific 
features of DHIs that need consideration if a trial is to provide useful evidence that supports 
rational decision making. These include: 
 
 the context in which the trial is undertaken; 
 the trade-off between external and internal validity; 
 specification of the intervention and delivery platform; 
 choice and specification of the comparator; and 
 establishing separate data collection methods from the DHI itself. 
 
The importance of context has been described in RQs 3 and 5. Understanding, defining, and 
describing the context in which an RCT is undertaken is necessary to inform judgments 
around the generalizability of the results outside the trial environment, particularly before 
implementing a DHI in a different context. 
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Deciding how to balance external and internal validity is a challenge for many trials,54 but is 
particularly salient for trials of DHIs. External validity refers to the extent to which the results 
apply to “a definable group of patients in a particular setting,” whereas internal validity is 
based on how the design and conduct of the trial minimizes potential for bias.55 The emphasis 
in trials of pharmaceutical products is on internal validity and reducing bias, and extensive 
work has confirmed the importance of this.56 However, there are real questions as to how 
well approaches developed to reduce bias in drug trials translate to trials of complex 
interventions in general 54 and to digital interventions in particular, including concerns about 
the degree to which design features that enhance internal validity jeopardize external validity. 
For example, poor retention to the trial, leading to missing follow-up data, may be countered 
by boosting the human component of the trial by undertaking some of the trial activities face 
to face, or by recruiting highly motivated participants who may be unrepresentative of the 
people who would use the intervention in routine practice. Hence, data from trials apparently 
at low risk of bias may paradoxically be less appropriate for informing policy than those with 
potentially greater risk of bias but better generalizability. 
 
Detailed specification of the DHI is important, but may be hard to achieve, particularly where 
there is a high degree of tailoring, adaptive learning, and user choice. Here, specification 
means having an agreed framework for classifying the intervention components, including 
the degree of human input and components that are individually tailored. Such specification 
is required for replication of trial results, comparison between DHIs, synthesizing data across 
trials in systematic reviews and meta-analyses,57 and may help with determining the criteria 
for “substantial equivalence” of DHIs. The concept of “substantial equivalence” is used for 
medical device and pharmaceutical regulation by the U.S. Food and Drug Administration and 
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similar regulatory bodies. Essentially, if a pivotal trial exists, interventions meeting criteria 
for “substantial equivalence” would not require further RCT evidence. For example, if a 
pivotal RCT (or meta-analysis) demonstrated effectiveness of a mindfulness-based DHI for 
depression, then each new mindfulness app for depression would not be required to undergo 
RCT testing—but instead to demonstrate substantial equivalence to existing “predicate” 
interventions.58 The relevant data to collect would then focus on usage, adherence, 
demographic access parameters, and user preferences. 
 
The selection of a suitable comparator is determined by the RQ that is addressed, which will 
vary with the stage of the research. In pragmatic trials that aim to determine the effectiveness 
of a new treatment compared to current best practice, the comparator is typically “treatment 
as usual.” However, in trials of DHIs, the participants in the treatment as usual group may 
have access to a myriad other DHIs. People accustomed to using DHIs are often also 
accustomed to searching online for resources. Someone who has sought help for a particular 
problem, entered a trial, been randomized to the comparator arm, and who finds the 
comparator intervention unhelpful, may well search online until they find a better resource.59 
This activity may be hard to prevent or track, but risks undermining the trial. 
 
In head-to-head RCTs, where the effects of two (or more) DHIs are compared with each other 
or against a face-to-face intervention, it is important to define which components of the 
comparator interventions are the same and which are different. Here, the specification of the 
comparator should follow the same principles as the specification of the intervention outlined 
above.57 
 
13 
There is a temptation in RCTs of DHIs to embed data collection into the intervention, but this 
may introduce systematic bias or confound the intervention with the measurement method. 
This bias may favor the intervention or, by more accurately recording adverse events, it may 
appear to show that the intervention is causing harm. 
 
Has the Possibility of Harm Been Adequately Considered? Has the Likelihood of Risks or 
Adverse Outcomes Been Assessed? 
DHIs are not harm free, although to date, the data on actual harms are relatively sparse. There 
are various mechanisms by which DHIs could result in harm. First, they could be designed to 
achieve an outcome that is widely viewed as harmful; for example, websites that promote 
suicide. Second, DHIs can make fraudulent claims, which if believed can result in the user 
experiencing harm. Examples of this include apps that claim to promote safer consumption of 
alcohol, including providing estimates of blood alcohol concentration to enable users to 
determine whether they are safe to drive, but do not in fact have any capacity to estimate 
blood alcohol concentration.60 Alternatively, a DHI could contain inaccurate information or 
advice. Third, a DHI could provide accurate information and advice, but this could be 
misinterpreted or wrongly applied, leading to that decisions that harm health. Alternatively, 
this accurate information could lead to increased anxiety or depression. Fourth, ineffective 
DHIs lead to opportunity costs for users, and if paid for by a health service, opportunity costs 
for the system. If individuals or systems put resources (funds, time, effort) into ineffective 
interventions, those resources are not available for effective interventions. Fifth, individuals 
(and systems) may become disillusioned and despondent if they use ineffective interventions, 
leading to a belief that either the individual is incapable of responding to treatment, or that all 
DHIs are useless and no further effort should be invested. Finally, DHIs may “leak” personal 
data because of inadequate security and encryption functions.47 
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All developers of DHIs should actively consider the possibility of harm and include 
evaluations that look for potential harms, including breaches of privacy and information 
governance. Identification and quantification of expected harms (such as increased anxiety) 
can be undertaken as part of an RCT, but unexpected harms will require alternative strategies 
for identification and quantification. Some may emerge during the development and 
optimization work, whereas others may require long-term observational studies during 
widespread implementation. 
 
Has Cost Been Adequately Considered and Measured? 
It is essential to consider sustainability and cost effectiveness from the very beginning of the 
development of a DHI. The development phase should include consideration of the long-term 
costs of maintenance and updating, how these costs could be met, and who will take 
responsibility for them. Methods for undertaking a formal health economic analysis are 
addressed in detail by 25. 
 
What is the Overall Assessment of the Utility of This Intervention? What is the Level of 
Confidence in this Assessment?  As a result of this Assessment, Should Research Priorities and 
/ or Clinical Practice Change?  
 
Answers to the previous ten questions should enable an assessment of the overall utility of 
the DHI (e.g., balancing its effects, usage, scalability, costs, safety), along with an estimate of 
confidence in this assessment. This in turn can guide decision making about research 
priorities and clinical practice. This assessment may range from considering that there is 
sufficient evidence of beneficial effect with sufficient confidence in the effect size along with 
adequate understanding of the costs, scalability, sustainability, and risks of harm for a 
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specific DHI that it should be incorporated into routine clinical practice, to realizing that a 
given DHI is so unlikely ever to have either sufficient clinical impact or reach that no further 
research resource should be invested in it. 
 
Discussion and Conclusions 
This paper outlines an RQ-driven approach to the evaluation of DHI, which should lead to an 
accumulating knowledge base around such interventions in a timely and resource-efficient 
manner. Good research in this area requires fertile multidisciplinary collaborations which 
draw on insights and experience from multiple fields, including clinical medicine, health 
services research, behavioral science, education, engineering, and computer science. 
Researchers from an engineering or computer science background may be surprised by the 
reliance on RCTs, whereas those from a biomedical or behavioral sciences background may 
consider there is too much emphasis on methods other than RCTs. The view put forward in 
this paper is that definitive, well-designed RCTs remain an important part of the overall 
toolkit for evaluating DHI, but only one part. Researchers in this field could learn from the 
iterative approach adopted by engineering and computer science where interventions undergo 
multiple cycles of development and optimization. A definitive trial should be undertaken only 
once: the intervention together with the delivery package around it have reached a degree of 
stability such that future developments can be considered relatively minor; there is reasonable 
confidence that the intervention plus delivery package can be implemented with high fidelity; 
and there is a reasonable likelihood that the overall benefits will be clinically meaningful and 
lead to either improved outcomes or equivalent outcomes at lower cost (Table 2). 
 
How best to combine rigor with efficiency in evaluating DHIs requires a great deal of 
methodologic research (Table 2). Areas to explore in future methodologic research include: 
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Enabling Individual Studies to Generate More-Useful Data: 
 consideration and validation of appropriate short-term proxy outcomes, together with 
identification of when use of these is appropriate, and when definitive outcomes such as 
health status are needed;  
 improving methods for early formative work, to make it as efficient as possible, and 
define if further investment in more intensive research designs and development 
processes is warranted; 
 better understanding of how to improve the internal validity of RCTs of DHIs in terms of 
retention and follow-up, without jeopardizing external validity in terms of the recruited 
population or impact on the intervention;  
 improved methods for reducing the large amounts of missing data that may occur, and 
addressing the inevitable biases this raises; and 
 better methods for determining whether and how a DHI will become scalable and 
sustainable, including understanding how a DHI might be supported through self-
sustaining business models.  
 
Enabling More Useful Synthesis and Comparison of Data Generated by Different Studies: 
 identification, specification, and classification of important contextual factors; 
 specification and classification of target populations; 
 specification and classification of DHIs, to gain an understanding of the important active 
components and mechanism of action, to replicate and synthesize evidence across DHI 
evaluations, and begin to address the issue of determining “substantial equivalence” 
between DHIs; 
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 specification and determination of appropriate comparators, according to the stage of the 
research process; and 
 improved reporting of studies of DHIs, building on initiatives such as the Template for 
Intervention Description and Replication reporting guideline57 and the CONSORT–
EHEALTH statement.61 
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Table 1. Key Research Questions for an Appraisal of a DHI 
Defining the problem 
1 Is there a clear health need which this DHI is intended to address? 
2 Is there a defined population which could benefit from this DHI? 
Defining the likely benefit of the DHI 
3 Is the DHI likely to reach this population, and if so, is the population likely to use it? 
4 Is there a credible causal explanation for the DHI to achieve the desired impact? 
5 What key components are needed for the DHI? Which components impact on the 
predicted outcome, and how do they interact with each other? 
6 What strategies should be used to support tailoring the DHI to participants over time? 
7 What is the likely direction and magnitude of the effect of the DHI or its components 
compared to a comparator which is meaningful for the stage of the research process? 
8 How confident are we about the magnitude of the effect of the DHI or its components 
compared to a comparator which is meaningful for the stage of the research process? 
9 Has the possibility of harms been adequately considered? And the likelihood of risks 
or adverse outcomes assessed? 
10 Has DHI cost and its cost impact on users and health systems been adequately 
considered and measured? 
11 What is the overall assessment of the utility of this intervention? How confident are 
we in this overall assessment? 
Decisions to be made based on our current knowledge 
12 Should we change research priorities? 
13 Should we change clinical practice? 
DHI, digital health intervention 
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Table 2. Key Guidance Points and Priority Topics for Future Research 
Guidance points based on existing research 
1 The efficient development of safe, effective, widely accessible DHIs requires 
innovative research methods to generate an accumulating knowledge base that can 
be used to guide decision making. 
2 Reach and uptake are crucial determinants of the overall impact of a DHI, and can be 
determined and improved using human-centered design methods. 
3 Sustainability and revenue models should be considered early in the development 
process. 
4 Defining a clear causal model that accounts for the multiple components of a DHI 
and the surrounding delivery package is essential. 
5 Identifying the essential or active components of a DHI or its delivery package can 
be done using a framework derived from engineering known as Multiphase 
Optimization Strategy (MOST). 
6 RCTs remain an important method for determining DHI impact in terms of 
effectiveness and cost-effectiveness, but are best undertaken once the DHI and its 
delivery package are stable, can be implemented with high fidelity, and are highly 
likely to lead to clinically meaningful benefits. 
Priority Topics for Future Research 
The key priority is to improve the efficiency of evaluations without jeopardizing rigor. 
Achieving this will entail: 
1 Enabling individual studies to generate more useful data through: improving 
methods of early formative work; better understanding of when and how short-term 
proxy outcomes should be used and when definitive outcomes are needed; better 
methods for improving internal validity of trials without jeopardizing external 
validity; improved methods for enhancing DHI uptake and minimizing missing data; 
and better methods for considering whether and how DHI will become scalable and 
sustainable. 
2 Enabling more useful synthesis and comparison of data generated by different 
studies through: improved specification and classification of context, target 
populations, digital health interventions and their components, using more 
appropriate comparators for the stage of the research process, and improved 
reporting of trials of DHI. 
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